CN116134144A - 细胞的hla-i类mhc消融 - Google Patents

细胞的hla-i类mhc消融 Download PDF

Info

Publication number
CN116134144A
CN116134144A CN202180044568.1A CN202180044568A CN116134144A CN 116134144 A CN116134144 A CN 116134144A CN 202180044568 A CN202180044568 A CN 202180044568A CN 116134144 A CN116134144 A CN 116134144A
Authority
CN
China
Prior art keywords
seq
cells
cell
vector
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180044568.1A
Other languages
English (en)
Chinese (zh)
Inventor
P·G·阿什顿-里卡德特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Az Treatment Co ltd
Original Assignee
Az Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Az Treatment Co ltd filed Critical Az Treatment Co ltd
Publication of CN116134144A publication Critical patent/CN116134144A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
CN202180044568.1A 2020-04-23 2021-04-23 细胞的hla-i类mhc消融 Pending CN116134144A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014344P 2020-04-23 2020-04-23
US63/014,344 2020-04-23
PCT/US2021/028808 WO2021216978A1 (en) 2020-04-23 2021-04-23 Cellular ablation of hla-class i mhc

Publications (1)

Publication Number Publication Date
CN116134144A true CN116134144A (zh) 2023-05-16

Family

ID=75888299

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180044568.1A Pending CN116134144A (zh) 2020-04-23 2021-04-23 细胞的hla-i类mhc消融

Country Status (6)

Country Link
US (1) US20230212585A1 (https=)
EP (1) EP4139458A1 (https=)
JP (1) JP7821119B2 (https=)
CN (1) CN116134144A (https=)
IL (1) IL297489A (https=)
WO (1) WO2021216978A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108572A1 (de) * 2004-05-06 2005-11-17 Medizinische Hochschule Hannover Verbindungen und verfahren zur immunsuppression
US20170016025A1 (en) * 2014-03-11 2017-01-19 Cellectis Method for generating t-cells compatible for allogenic transplantation
WO2018208837A1 (en) * 2017-05-08 2018-11-15 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
CN109804064A (zh) * 2016-09-29 2019-05-24 南克维斯特公司 具有降低的免疫原性的hla i类缺陷的nk-92细胞

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US8236771B2 (en) 2004-05-18 2012-08-07 National Institute Of Transplantation Foundation Vectors and methods for long-term immune evasion to prolong transplant viability
US9997807B2 (en) 2014-12-24 2018-06-12 East Penn Manufacturing Co. Vibration resistant valve assembly for lead acid batteries
EP3441461A1 (en) * 2017-08-11 2019-02-13 Baylor College of Medicine Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
EP3773629A4 (en) 2018-03-27 2022-01-19 AZTherapies, Inc. CAR-TREG-BASED THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
KR102691932B1 (ko) * 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108572A1 (de) * 2004-05-06 2005-11-17 Medizinische Hochschule Hannover Verbindungen und verfahren zur immunsuppression
US20170016025A1 (en) * 2014-03-11 2017-01-19 Cellectis Method for generating t-cells compatible for allogenic transplantation
CN109804064A (zh) * 2016-09-29 2019-05-24 南克维斯特公司 具有降低的免疫原性的hla i类缺陷的nk-92细胞
WO2018208837A1 (en) * 2017-05-08 2018-11-15 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof

Also Published As

Publication number Publication date
US20230212585A1 (en) 2023-07-06
JP7821119B2 (ja) 2026-02-26
IL297489A (en) 2022-12-01
WO2021216978A1 (en) 2021-10-28
EP4139458A1 (en) 2023-03-01
JP2023522985A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
CN109803983B (zh) 靶向nkg2dl的特异性嵌合抗原受体t细胞，其制备方法和应用
JP2023115069A (ja) 造血幹細胞における遺伝子編集のための方法および組成物
EP4678184A2 (en) Engineered chimeric fusion protein compositions and methods of use thereof
US20240139320A1 (en) Chimeric antigen receptor (car) signaling molecules for controlled and specific car t cell activity
IL274299B1 (en) Methods, compositions and components for editing TGFBR2 by CRISPR-Cas9 in T cells for immunotherapy
JP7412666B2 (ja) ＨＰＫ１を標的とするｇＲＮＡ及びＨＰＫ１遺伝子の編集方法
TW201840845A (zh) 保護移植組織免受排斥的方法
US20220001031A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
KR20210043623A (ko) Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포
US20220119476A1 (en) Activation of Antigen Presenting Cells and Methods for Using the Same
US20220378824A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
US20250025558A1 (en) Engineered Chimeric Antigen Receptor (CAR) Microglia-Like Cells for the Treatment of Neurodegenerative Disorders
CN113896801A (zh) 靶向人Claudin18.2和NKG2DL的嵌合抗原受体细胞及其制备方法和应用
CN112500497B (zh) Cltx-nkg2d双特异性嵌合抗原受体细胞及其制备方法和应用
EP3766977A1 (en) Genetically modified cell and producing method therefor
US20260042815A1 (en) Universal t cells and compositions and methods of use thereof
JP7821119B2 (ja) Ｈｌａクラスｉ ｍｈｃの細胞切除
JP2023509058A (ja) Ｔ細胞リンパ腫細胞を標的とするユニバーサルｃａｒ－ｔならびにその調製方法及び使用
JP2025520384A (ja) 改善されたグリカン依存性キメラ抗原受容体細胞
US20230242666A1 (en) Methods and Compositions for the Reduction of Chimeric Antigen Receptor Tonic Signaling
US20250304913A1 (en) Chimeric antigen receptor t cells and methods of use thereof
US20230183315A1 (en) Regulatory T Cells Expressing Chimeric Antigen Receptors and Uses in Synucleinopathies
US12258379B2 (en) Compositions and methods for switchable CAR T cells using surface-bound sortase transpeptidase
HK40126591A (zh) 通用t细胞和组合物及它们的使用方法
WO2025241667A1 (zh) 一种降低t细胞免疫原性的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination